Talphera 

€0.68
58
+€0.02+3.03% Friday 06:06

Statistics

Day High
0.62
Day Low
0.62
52W High
1.24
52W Low
0.3
Volume
-
Avg. Volume
-
Mkt Cap
31.69M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.19
-0.15
-0.1
-0.05
Expected EPS
-0.059696000000000006
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-24.62MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow R5XA.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap298.84B
Merck & Co., Inc. is a leading global biopharmaceutical company that competes with Talphera in the development and marketing of prescription medicines, vaccines, biologic therapies, and animal health products.
Pfizer
PFE
Mkt Cap161.09B
Pfizer Inc. is a global pharmaceutical corporation which competes directly with Talphera in various therapeutic areas, including oncology, rare diseases, and immunology.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol Myers Squibb is a global biopharmaceutical company that competes with Talphera in the discovery, development, and delivery of innovative medicines that help patients prevail over serious diseases.
Gilead Sciences
GILD
Mkt Cap173.41B
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need, competing with Talphera in the fields of antiviral drugs, cancer, and other diseases.
Abbvie
ABBV
Mkt Cap369.39B
AbbVie Inc. is a research-based biopharmaceutical company that develops and markets advanced therapies, competing with Talphera in areas such as immunology and oncology.
AMGEN
AMGN
Mkt Cap187.56B
Amgen Inc. is one of the world's leading biotechnology companies, competing with Talphera in developing innovative human therapeutics, including treatments for serious illnesses.
Johnson & Johnson
JNJ
Mkt Cap585.7B
Johnson & Johnson is a comprehensive healthcare company that competes with Talphera through its pharmaceutical segment, developing drugs for a wide range of medical conditions.
Novartis
NVS
Mkt Cap297.32B
Novartis AG is a global healthcare company based in Switzerland that competes with Talphera in researching, developing, manufacturing, and marketing a broad range of healthcare products.
Roche
RHHBY
Mkt Cap321.08B
Roche Holding AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Roche competes with Talphera in the pharmaceutical sector, particularly in oncology and virology.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biopharmaceutical company that competes with Talphera in developing and commercializing prescription medicines for several therapeutic areas, including cancer, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

About

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, a nafamostat formulation for direct IV infusion as an investigational product for various indications, such as antiviral, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis, as well as Fedsyra and phenylephrine ready-to-use pre-filled syringe product candidates. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is based in San Mateo, California.
Show more...
CEO
Mr. Vincent J. Angotti
Employees
12
Country
Germany
ISIN
US00444T2096
WKN
000A3DWPN

Listings

0 Comments

Share your thoughts

FAQ

What is Talphera stock price today?
The current price of R5XA.F is €0.68 EUR — it has increased by +3.03% in the past 24 hours. Watch Talphera stock price performance more closely on the chart.
What is Talphera stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Talphera stocks are traded under the ticker R5XA.F.
Is Talphera stock price growing?
R5XA.F stock has risen by +4.45% compared to the previous week, the month change is a -9.93% fall, over the last year Talphera has showed a +58.51% increase.
What is Talphera market cap?
Today Talphera has the market capitalization of 31.69M
When is the next Talphera earnings date?
Talphera is going to release the next earnings report on May 18, 2026.
What were Talphera earnings last quarter?
R5XA.F earnings for the last quarter are -0.05 EUR per share, whereas the estimation was -0.06 EUR resulting in a +20% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Talphera revenue for the last year?
Talphera revenue for the last year amounts to 0 EUR.
What is Talphera net income for the last year?
R5XA.F net income for the last year is -24.62M EUR.
How many employees does Talphera have?
As of April 12, 2026, the company has 12 employees.
In which sector is Talphera located?
Talphera operates in the Health & Wellness sector.
When did Talphera complete a stock split?
The last stock split for Talphera was on October 26, 2022 with a ratio of 1:20.
Where is Talphera headquartered?
Talphera is headquartered in San Mateo, Germany.